This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Seoul National University. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Innovations of Jin-A Kang in Stem Cell Research
Introduction
Jin-A Kang is an accomplished inventor based in Incheon, South Korea. He has made significant contributions to the field of stem cell research, particularly in the area of angiogenesis. His innovative work has the potential to impact various medical conditions that require enhanced blood vessel formation.
Latest Patents
Jin-A Kang holds a patent for "Peripheral blood stem cells with improved angiogenic properties and use thereof." This patent discloses a method for producing peripheral blood stem cells with enhanced angiogenic properties through EPO or APS priming. The cells produced using this method are capable of inducing angiogenesis, making them effective for the regeneration of tissues affected by ischemic diseases. These diseases can occur in various organs, including the muscle, brain, heart, kidney, and large intestine.
Career Highlights
Jin-A Kang is affiliated with Seoul National University, where he conducts research and develops innovative solutions in the field of stem cell therapy. His work focuses on addressing critical health issues related to ischemic conditions, such as myocardial infarction and stroke. With a patent portfolio that includes 1 patent, he continues to advance the understanding and application of stem cell technology.
Collaborations
Jin-A Kang collaborates with notable colleagues, including Jeehoon Kang and Ji-Yeon Yun. Their combined expertise enhances the research efforts at Seoul National University, fostering an environment of innovation and discovery.
Conclusion
Jin-A Kang's contributions to stem cell research exemplify the potential of innovative methods in medical science. His work not only advances academic knowledge but also holds promise for practical applications in treating ischemic diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
